TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00792636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan and naproxen sodium combination tablet
Description: sumatriptan 85mg and naproxen sodium 500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan tablet
Description: sumatriptan 85mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium tablet
Description: Naproxen sodium 500mg
Study: NCT01046136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guaifenesin (Mucinex)
Description: bid 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bid 7 days
Study: NCT04373434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Homes/Healthy Families (HH/HF) Intervention
Description: The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study.
Study: NCT03592602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm abduction and adduction
Description: All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
Study: NCT01462149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5, q 3 weeks, 3 cycles
Study: NCT05532371

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only lower limb strengthening group (CG)
Description: The participants performed only lower limb strengthening group during this intervention.
Study: NCT03751618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Description: Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip arthroscopy
Description: Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure.
Study: NCT01234922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benazepril hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: Given orally
Study: NCT00886223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic robot-assisted sacropexy
Description: Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
Study: NCT01348412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m²Every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: 3 mg/m² with a maximum of 6 mg every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other intravenous chemotherapy drugs
Study: NCT03533738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 1
Description: Vegetables first then meat \& rice together

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 2
Description: Meat first then vegetables \& rice together

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 3
Description: Vegetables first then meat followed by rice
Study: NCT01746641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT03533738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 4
Description: Vegetables first followed by meat and rice together
Study: NCT01746641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT02065193

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment
Study: NCT03533738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food sequence 5
Description: Rice first followed by vegetables \& meat together
Study: NCT04171206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free From Abuse
Description: Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Technology and crime
Description: Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
Study: NCT04699851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored recommendations
Description: Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General recommendation
Description: The control group will receive general recommendations by email about health prevention in a pandemic.
Study: NCT05231330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silvernanoparticles
Description: silvernanoparticles in fluoride varnish

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SDF
Description: silver diamine fluoride
Study: NCT05395455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
Study: NCT03067961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi (S. Typhi)
Description: Investigating the role of typhoid toxin in the pathogenesis of enteric fever

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi (S. Typhi)
Description: Investigating the role of typhoid toxin in the pathogenesis of enteric fever
Study: NCT03060629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo.
Study: NCT06237998

Intervention type: DEVICE
Intervention: Telemedicine
Description: Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
Study: NCT01666782

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Trivalent Influenza Vaccine
Description: Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Influenza Vaccine
Description: Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
Study: NCT05315128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: A randomized comparative effectiveness clinical trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: A randomized comparative effectiveness clinical trial
Study: NCT02505867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servo Ventilation
Description: Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
Study: NCT01886352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional injection of 0,5% levobupivacaine.
Description: Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal atomization of levobupivacaine.
Description: Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg.
Study: NCT03655418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience Curriculum (RESCUR)
Description: The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience.
Study: NCT01124513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induced Erythema
Description: Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induced Erythema
Description: Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
Study: NCT02065193

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment
Study: NCT01124513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induced Erythema
Description: Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
Study: NCT01794546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
Study: NCT04031391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels
Study: NCT03971214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor JS-001
Description: The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
Study: NCT02695329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KneeAlign 2
Description: Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
Study: NCT02393170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-training using video-games
Description: Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional self-training
Description: Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
Study: NCT02366052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Nutritional counseling by a trained nutritionist for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei shirota (LCS)
Description: The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
Study: NCT02065193

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment

Intervention type: BEHAVIORAL
Intervention: ADOS/ADI-R/Clinical assessment
Study: NCT01794546

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth
Description: Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
Study: NCT00179998

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human DNase (Pulmozyme)
Description: 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human DNase (Pulmozyme)
Description: 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: 2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
Study: NCT03399786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: IV administration of evinacumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV administration of placebo
Study: NCT00868361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel (non-radiolabeled), [14C] Talampanel
Description: 50 mg capsule single dose
Study: NCT01637857

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: sham oligoantigenic diet associated to lifestyle instruction
Description: sham oligoantigenic diet associated to lifestyle instruction

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oligoantigenic diet
Description: oligoantigenic diet associated to life style counseling
Study: NCT01791790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation
Study: NCT02366052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling and LCS
Description: Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
Study: NCT02997020

Intervention type: OTHER
Intervention: EDSPD
Description: The equipment \& conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
Study: NCT01791790

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: no stimulation